The Polycystic Kidney Disease Research Resource Consortium (PKD RRC) develops and shares investigative resources, reagents and expertise with the broader research community to accelerate innovation and discovery in the field of polycystic kidney disease. Explore our resources and core services to see how we can help you advance your research goals.
News, Events & Publications
@pkdresearch.bsky.social on Bluesky
Recent Publications
- Embryological and Clinical Outcomes in Couples With Autosomal Dominant Polycystic Kidney Disease Undergoing PGT-M: A Retrospective Cohort Study.
- Genetic Spectrum and Family-Based Cascade Screening in Vietnamese Families With Autosomal Dominant Polycystic Kidney Disease.
- CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant.
- Assessment of CFTR Dysfunction and Responsiveness to CFTR Modulators in COPD Bronchial Air-Liquid Interface Cultures.
- Clinical and Genetic Interplay Between Chronic Pancreatitis, Cystic Fibrosis and CFTR-Related Disorders.
- Comparison of Prime Editing and CRISPR-Cas Mediated HDR in Correcting CFTR-F508del Mutation in Patient iPSC-Derived Airway Basal Cells.
- Late-Diagnosed Cystic Fibrosis with Co-Occurring CFTR 3849+10kbC>T and 5T Variants: A Case Report.
- A phase 2a study with SPL84: A novel RNA-targeted approach to restore CFTR function in people with CF carrying the 3849+10 kb C→T mutation.
- Integrated expression profiling and structure-based drug discovery identify EGFR as a druggable target and Tripterygium wilfordii phytochemicals as potential therapeutics for autosomal dominant polycystic kidney disease.
- CFTR variant-associated hereditary pancreatitis complicated by diabetes mellitus: a case report and literature review.
- Chronic Pain in Autosomal Dominant Polycystic Kidney Disease and the Long-Term Effects of Increasing Water Intake.
- Perspectives on inhaled medicines in the CFTR modulator era: A national survey of adults with cystic fibrosis.
- Defective Inflammation Resolution in Cystic Fibrosis: Cellular Mechanisms and Emerging Pro-resolving Therapies in the CFTR Modulator Era.
- Laparoscopic resection of a low-grade appendiceal mucinous neoplasm in a patient with autosomal dominant polycystic kidney disease: a case report.
- PKD2 structural destabilization drives primary cilia degeneration and ADPKD pathogenicity.
- Analysis of brain iron deposition in an in vivo model of pediatric autosomal dominant polycystic kidney disease.
- Per-oral pancreatoscopy-guided pancreatic duct biopsy collection in chronic pancreatitis patients allows culture of organoids suitable for assessing CFTR function.
- Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients With Severe Lung Disease Carrying Previously Ineligible CFTR Mutations.
- Residual-Function and Splicing CFTR Variants Characterize False-Negative IRT Newborn Screening: A Ten-Year Single-Center Cohort From Türkiye.
- Corrigendum to "Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant" [J Cyst Fibros 24 (2025) 542-547].
- Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells.
- Atypical cranio-orbital perineural cysts in autosomal-dominant polycystic kidney disease.
- Corrigendum to "Multisystemic impact of autosomal dominant polycystic kidney disease: A case report highlighting renal, hepatic, and neurological involvement" [Radiology Case Reports, volume 20, issue 4, 2025, pages 2093-2100].
- Development of a prediction model for aneurysmal events to guide imaging surveillance in autosomal dominant polycystic kidney disease.
- Adverse Events Associated with CFTR Modulator Therapy: Experience from a Tertiary Care Center.
- Analysis of CFTR mutation spectrum in Yugra region (Russian Federation).
